3 maio 2016 ano - FDA convened a joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee to discuss results from assessments of the extended-release and long- acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategies (REMS)
Adicionado na linha do tempo:
Data:
3 maio 2016 ano
Agora
~ 9 years and 5 months ago